Cytek Biosciences Reports Second Quarter 2024 Financial Results
Cytek Biosciences (Nasdaq: CTKB) reported Q2 2024 financial results with total revenue of $46.6 million, a 4% sequential increase but a 6% year-over-year decrease. The company faced weakness in U.S. instrument sales, particularly among academic and government customers, offset by strong growth in EMEA and APAC regions. Cytek's installed base reached 2,656 instruments, adding 147 units in Q2. The company reported a net loss of $10.4 million and adjusted EBITDA of $2.9 million. Cytek narrowed its 2024 revenue guidance to $203-$210 million, representing 5-9% growth over 2023. The company expects a single-digit million net loss for 2024 but anticipates positive cash flow from operations.
Cytek Biosciences (Nasdaq: CTKB) ha riportato i risultati finanziari del secondo trimestre 2024, con un fatturato totale di 46,6 milioni di dollari, registrando un aumento sequenziale del 4% ma una diminuzione del 6% rispetto all'anno precedente. L'azienda ha affrontato una debolezza nelle vendite di strumenti negli Stati Uniti, in particolare tra i clienti accademici e governativi, compensata da una forte crescita nelle regioni EMEA e APAC. Il parco installato di Cytek ha raggiunto 2.656 strumenti, con un incremento di 147 unità nel secondo trimestre. L'azienda ha segnalato una perdita netta di 10,4 milioni di dollari e un EBITDA rettificato di 2,9 milioni di dollari. Cytek ha ridotto la sua previsione di fatturato per il 2024 a 203-210 milioni di dollari, indicando una crescita del 5-9% rispetto al 2023. L'azienda si aspetta una perdita netta di alcuni milioni per il 2024, ma prevede un flusso di cassa positivo dalle operazioni.
Cytek Biosciences (Nasdaq: CTKB) reportó los resultados financieros del segundo trimestre de 2024, con ingresos totales de 46,6 millones de dólares, un aumento secuencial del 4% pero una disminución del 6% en comparación con el año anterior. La compañía enfrentó debilidad en las ventas de instrumentos en EE. UU., especialmente entre clientes académicos y gubernamentales, contrarrestada por un fuerte crecimiento en las regiones EMEA y APAC. La base instalada de Cytek alcanzó 2,656 instrumentos, añadiendo 147 unidades en el segundo trimestre. La compañía reportó una pérdida neta de 10,4 millones de dólares y un EBITDA ajustado de 2,9 millones de dólares. Cytek ha ajustado su guía de ingresos para 2024 a 203-210 millones de dólares, representando un crecimiento del 5-9% respecto a 2023. La empresa espera una pérdida neta de millones de dólares de un solo dígito para 2024, pero anticipa un flujo de caja positivo de las operaciones.
Cytek Biosciences (Nasdaq: CTKB)는 2024년 2분기 재무 실적을 보고하며 총 수익 4,660만 달러를 기록했으며, 이는 순차적으로 4% 증가했지만 전년 대비 6% 감소한 수치입니다. 이 회사는 미국의 기기 판매 부진에 직면했으며, 특히 학술 및 정부 고객들 사이에서 그러한 경향이 두드러졌고, EMEA 및 APAC 지역에서는 강력한 성장이 있었습니다. Cytek의 설치된 기기 수는 2,656대에 이르렀으며, 2분기 동안 147대를 추가했습니다. 이 회사는 1,040만 달러의 순손실과 290만 달러의 조정된 EBITDA를 보고했습니다. Cytek은 2024년 수익 전망을 2억 3천만에서 2억 1천만 달러로 좁히며, 이는 2023년에 비해 5-9% 성장하는 것을 의미합니다. 이 회사는 2024년에 단일 자릿수의 백만 달러 수준의 순손실을 예상하지만 운영에서 긍정적인 현금 흐름을 기대하고 있습니다.
Cytek Biosciences (Nasdaq: CTKB) a annoncé les résultats financiers du deuxième trimestre de 2024, avec un chiffre d'affaires total de 46,6 millions de dollars, en hausse de 4% par rapport au trimestre précédent mais en baisse de 6% par rapport à l'année précédente. L'entreprise a rencontré une faiblesse dans les ventes d'instruments aux États-Unis, notamment chez les clients académiques et gouvernementaux, compensée par une forte croissance dans les régions EMEA et APAC. La base installée de Cytek a atteint 2 656 instruments, ajoutant 147 unités au deuxième trimestre. L'entreprise a signalé une perte nette de 10,4 millions de dollars et un EBITDA ajusté de 2,9 millions de dollars. Cytek a réduit ses prévisions de revenus pour 2024 à 203-210 millions de dollars, représentant une croissance de 5 à 9 % par rapport à 2023. L'entreprise s'attend à une perte nette de quelques millions de dollars pour 2024, mais prévoit un flux de trésorerie positif provenant des opérations.
Cytek Biosciences (Nasdaq: CTKB) hat die Finanzergebnisse für das zweite Quartal 2024 bekannt gegeben, mit Gesamtumsätzen von 46,6 Millionen US-Dollar, was einem sequenziellen Anstieg von 4% entspricht, aber einem Rückgang von 6% im Jahresvergleich. Das Unternehmen sah sich Schwächen beim Verkauf von Instrumenten in den USA gegenüber, insbesondere bei akademischen und staatlichen Kunden, die jedoch durch starkes Wachstum in den Regionen EMEA und APAC ausgeglichen wurden. Der installierte Bestand von Cytek erreichte 2.656 Instrumente, mit 147 zusätzlichen Einheiten im 2. Quartal. Das Unternehmen meldete einen Nettoverlust von 10,4 Millionen US-Dollar und ein bereinigtes EBITDA von 2,9 Millionen US-Dollar. Cytek hat die Umsatzprognose für 2024 auf 203–210 Millionen US-Dollar verengt, was einem Wachstum von 5–9% gegenüber 2023 entspricht. Das Unternehmen erwartet für 2024 einen Nettoverlust im niedrigen einstelligen Millionenbereich, rechnet jedoch mit einem positiven Cashflow aus den Betrieben.
- Total revenue increased 4% sequentially to $46.6 million in Q2 2024
- Strong double-digit revenue growth in EMEA and APAC regions
- Total installed base reached 2,656 instruments, adding 147 units in Q2 2024
- Adjusted EBITDA improved to $2.9 million from $1.5 million in Q2 2023
- Cash and marketable securities increased by $6.8 million to $277.2 million
- Company expects positive cash flow from operations in 2024
- Total revenue decreased 6% year-over-year in Q2 2024
- Weakness in U.S. instrument sales, particularly among academic and government customers
- Net loss increased to $10.4 million from $4.4 million in Q2 2023
- Gross profit margin declined to 55% from 57% in Q2 2023
- Company narrowed 2024 revenue guidance, expecting single-digit million net loss for the year
Insights
Cytek Biosciences' Q2 2024 results present a mixed picture. While total revenue decreased
The company's gross profit margin slightly decreased to
Positively, Cytek's cash position improved to
Cytek's Q2 results reveal regional disparities in market performance. The company experienced strong double-digit growth in EMEA and APAC regions, contrasting with weakness in the U.S. market. This suggests a shift in global demand patterns for cell analysis solutions, potentially influenced by varying economic conditions and research funding landscapes across regions.
The launch of Enhanced Small Particle (ESP™) detection demonstrates Cytek's commitment to product innovation, addressing the growing need for virus and sub-cellular component analysis. This could help maintain Cytek's competitive edge in a rapidly evolving market.
The increase in total installed base to 2,656 instruments, including 147 new units in Q2, indicates continued market penetration. However, the YoY revenue decline suggests potential pricing pressures or a shift towards lower-priced models. The company's focus on executing its business strategy for durable growth and profitability will be important in navigating these market dynamics.
FREMONT, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024.
Recent Highlights
- Total revenue for the second quarter of 2024 was
$46.6 million , representing a4% increase sequentially over the first quarter of 2024 and a6% decrease over the second quarter of 2023 - For the first half of 2024, total revenue grew
5% compared to the first half of 2023 - Launched Enhanced Small Particle (ESP™) detection, an upgrade option for the Cytek Aurora™ and Northern Lights™ systems for the analysis of viruses and other sub-cellular components
- Attained a total installed base of 2,656 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the flow cytometry and imaging business from Luminex Corporation in February 2023, adding 147 units in the second quarter of 2024
- Repurchased
$2.7 million of Cytek stock in open market purchases during the second quarter of 2024 under a new$50 million share repurchase program, following the expiration of the previous$50 million repurchase program at the end of 2023
“In the second quarter of 2024, we posted strong year over year double-digit revenue growth in EMEA and APAC as well as in our service business worldwide as compared to the second quarter of 2023. However, this performance was offset by a decline in our U.S. instrument sales, particularly among academic and government customers,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences. “Despite the headwinds in the U.S. market, we believe the fundamental drivers of long-term growth remain in place, and the underlying opportunity for our products remains strong. We remain focused on executing our business strategy and delivering durable growth and profitability and strong value to our customers and shareholders.”
Second Quarter 2024 Financial Results
Total revenue for the second quarter of 2024 was
Gross profit was
Operating expenses were
Research and development expenses were
Sales and marketing expenses were
General and administrative expenses were
Loss from operations in the second quarter of 2024 was
Adjusted EBITDA in the second quarter of 2024 was
Cash and marketable securities were
2024 Outlook
Cytek Biosciences narrowed the range of its 2024 revenue guidance, now expecting full year 2024 revenue to in the range of
Webcast Information
Cytek will host a conference call to discuss its second quarter 2024 financial results on Tuesday, August 6, 2024, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle (ESP™) detection technology, the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Statement Regarding Use of Non-GAAP Financial Information
Cytek has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three-month periods ended June 30, 2024 and June 30, 2023. Management believes that non-GAAP financial measures, including “Adjusted gross profit margin” and “Adjusted EBITDA” referenced above, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding Cytek’s plans and strategies to deliver durable growth and profitability and strong value to its customers and shareholders; Cytek’s long term growth and opportunity in the U.S. market; Cytek’s business opportunities and market demand for advanced cell analysis solutions; and Cytek’s future financial performance, including its outlook for fiscal year 2024. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global economic and market conditions; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and retain key employees; Cytek’s ability to maintain, protect and enhance its intellectual property; and Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Cytek’s most recent Annual Report on Form 10-K filed with the SEC on March 13, 2024, Cytek’s Quarterly Report on Form 10-Q to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Relations Contact:
Paul D. Goodson
Head of Investor Relations
pgoodson@cytekbio.com
| Cytek Biosciences, Inc. Consolidated Balance Sheets | ||||||||
| (In thousands, except share and per share data) | June 30, 2024 | December 31, 2023 | ||||||
| (unaudited) | (audited) | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 177,888 | $ | 167,299 | ||||
| Restricted cash | 30 | 331 | ||||||
| Marketable securities | 99,323 | 95,111 | ||||||
| Trade accounts receivable, net | 44,643 | 55,928 | ||||||
| Inventories | 50,070 | 60,877 | ||||||
| Prepaid expenses and other current assets | 12,130 | 12,514 | ||||||
| Total current assets | 384,084 | 392,060 | ||||||
| Deferred income tax assets, noncurrent | 29,676 | 30,487 | ||||||
| Property and equipment, net | 18,114 | 18,405 | ||||||
| Operating lease right-of-use assets | 9,328 | 10,853 | ||||||
| Goodwill | 16,183 | 16,183 | ||||||
| Intangible assets, net | 21,420 | 23,084 | ||||||
| Other noncurrent assets | 4,920 | 3,385 | ||||||
| Total assets | $ | 483,725 | $ | 494,457 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Trade accounts payable | $ | 3,191 | $ | 3,032 | ||||
| Legal settlement liability, current | 2,503 | 2,561 | ||||||
| Accrued expenses | 15,489 | 20,035 | ||||||
| Other current liabilities | 7,228 | 7,903 | ||||||
| Deferred revenue, current | 23,968 | 22,695 | ||||||
| Total current liabilities | 52,379 | 56,226 | ||||||
| Legal settlement liability, noncurrent | 16,912 | 16,477 | ||||||
| Deferred revenue, noncurrent | 14,064 | 15,132 | ||||||
| Operating lease liability, noncurrent | 8,113 | 9,479 | ||||||
| Long term debt | 1,330 | 1,648 | ||||||
| Other noncurrent liabilities | 1,804 | 2,431 | ||||||
| Total liabilities | $ | 94,602 | $ | 101,393 | ||||
| Stockholders’ equity: | ||||||||
| Common stock, | 132 | 131 | ||||||
| Additional paid-in capital | 434,967 | 423,386 | ||||||
| Accumulated deficit | (45,781 | ) | (29,178 | ) | ||||
| Accumulated other comprehensive loss | (195 | ) | (1,275 | ) | ||||
| Total stockholders’ equity | 389,123 | 393,064 | ||||||
| Total liabilities and stockholders’ equity | $ | 483,725 | $ | 494,457 | ||||
| Cytek Biosciences, Inc. Consolidated Statements of Operations and Comprehensive Loss (unaudited) | ||||||||||||||||
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| (In thousands, except share and per share data) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue, net: | ||||||||||||||||
| Product | $ | 34,576 | $ | 40,452 | $ | 68,698 | $ | 71,624 | ||||||||
| Service | 12,041 | 9,241 | 22,779 | 15,157 | ||||||||||||
| Total revenue, net | 46,617 | 49,693 | 91,477 | 86,781 | ||||||||||||
| Cost of sales: | ||||||||||||||||
| Product | 15,808 | 16,675 | 32,554 | 29,352 | ||||||||||||
| Service | 5,373 | 4,856 | 10,474 | 8,229 | ||||||||||||
| Total cost of sales | 21,181 | 21,531 | 43,028 | 37,581 | ||||||||||||
| Gross profit | 25,436 | 28,162 | 48,449 | 49,200 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 10,001 | 12,136 | 19,796 | 22,110 | ||||||||||||
| Sales and marketing | 12,268 | 14,367 | 24,811 | 25,512 | ||||||||||||
| General and administrative | 11,694 | 10,786 | 23,102 | 22,867 | ||||||||||||
| Total operating expenses | 33,963 | 37,289 | 67,709 | 70,489 | ||||||||||||
| Loss from operations | (8,527 | ) | (9,127 | ) | (19,260 | ) | (21,289 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | (134 | ) | (409 | ) | (575 | ) | (1,082 | ) | ||||||||
| Interest income | 1,416 | 1,201 | 2,775 | 3,344 | ||||||||||||
| Other income, net | 59 | 1,740 | 881 | 3,392 | ||||||||||||
| Total other income, net | 1,341 | 2,532 | 3,081 | 5,654 | ||||||||||||
| Loss before income taxes | (7,186 | ) | (6,595 | ) | (16,179 | ) | (15,635 | ) | ||||||||
| Provision for (benefit from) income taxes | 3,248 | (2,207 | ) | 424 | (4,440 | ) | ||||||||||
| Net loss | (10,434 | ) | (4,388 | ) | (16,603 | ) | (11,195 | ) | ||||||||
| Net loss, basic and diluted | $ | (10,434 | ) | $ | (4,388 | ) | $ | (16,603 | ) | $ | (11,195 | ) | ||||
| Net loss per share, basic | $ | (0.08 | ) | $ | (0.03 | ) | $ | (0.13 | ) | $ | (0.08 | ) | ||||
| Net loss per share, diluted | $ | (0.08 | ) | $ | (0.03 | ) | $ | (0.13 | ) | $ | (0.08 | ) | ||||
| Weighted-average shares used in calculating net loss per share, basic | 131,440,486 | 135,918,707 | 131,180,734 | 135,705,139 | ||||||||||||
| Weighted-average shares used in calculating net loss per share, diluted | 131,440,486 | 135,918,707 | 131,180,734 | 135,705,139 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (10,434 | ) | $ | (4,388 | ) | $ | (16,603 | ) | $ | (11,195 | ) | ||||
| Foreign currency translation adjustment, net of tax | 1,375 | (980 | ) | 1,131 | (1,022 | ) | ||||||||||
| Unrealized loss on marketable securities | (16 | ) | (192 | ) | (51 | ) | (40 | ) | ||||||||
| Net comprehensive loss | $ | (9,075 | ) | $ | (5,560 | ) | $ | (15,523 | ) | $ | (12,257 | ) | ||||
| Cytek Biosciences, Inc. Reconciliation of GAAP to Non-GAAP Measures (Unaudited) | ||||||||
| Three months ended | ||||||||
| (In thousands) | June 30, 2024 | June 30, 2023 | ||||||
| (Unaudited) | (Unaudited) | |||||||
| GAAP Gross Profit | $ | 25,436 | $ | 28,162 | ||||
| Stock Based Compensation | $ | 1,200 | $ | 868 | ||||
| Amortization of Acquisition-related Intangible assets | $ | 503 | $ | 539 | ||||
| Adjusted Gross Profit (Non-GAAP) | $ | 27,139 | $ | 29,569 | ||||
| Adjusted Gross Profit Margin (Non-GAAP) % | 58 | % | 60 | % | ||||
| GAAP Net Loss | $ | (10,434 | ) | $ | (4,388 | ) | ||
| Depreciation and Amortization | $ | 2,479 | $ | 2,445 | ||||
| Benefit From Income Taxes | $ | 3,248 | $ | (2,207 | ) | |||
| Interest Income | $ | (1,416 | ) | $ | (1,201 | ) | ||
| Interest Expense | $ | 134 | $ | 409 | ||||
| Foreign Currency Exchange Loss | $ | 1,784 | $ | 535 | ||||
| Stock Based Compensation | $ | 7,152 | $ | 5,922 | ||||
| Acquisition Related Expenses | $ | — | $ | 27 | ||||
| Adjusted EBITDA (Non-GAAP) | $ | 2,947 | $ | 1,542 | ||||
FAQ
What was Cytek Biosciences' (CTKB) revenue for Q2 2024?
How many instruments did Cytek Biosciences (CTKB) add to its installed base in Q2 2024?
What is Cytek Biosciences' (CTKB) revenue guidance for full year 2024?
Did Cytek Biosciences (CTKB) report a profit or loss in Q2 2024?
